文献速递结核与非结核分枝杆菌

中国成功治疗后的肺结核复发:一项基于人群的回顾性研究

Recurrent pulmonary tuberculosis after treatment success: a population-based retrospective study in China.
PubMed 文献 · Clin Microbiol Infect · 2021-09-30

中位观察1565天,复发率4.9%,51.1%的复发发生在1年内,2年和5年累积复发率分别为3.90%和5.4%。男性、年龄≥60岁、空洞及2个月痰菌阳性增加复发风险,延长治疗与复发风险降低相关。

要点

  • 成功治疗的涂阳肺结核患者5年累积复发率为5.4%。
  • 过半复发发生在治疗成功后1年内。
  • 男性、≥60岁、空洞、2月痰阳性为复发独立危险因素。

核心结论

  • 成功治疗的涂片阳性肺结核患者仍存在复发问题,具有独立危险因素者尤需关注。
  • 延长治疗与复发风险降低相关,但需进一步分析。

研究设计与样本

  • 最终分析9,828例成功治疗患者,中位观察期1565天。

主要发现

  • 复发率4.9%(479/9828),51.1%(245/479)的复发发生在1年内。
  • 2年累积复发率3.90%(95%CI 3.3-4.5%),5年累积复发率5.4%(95%CI 4.8-6.0%)。
  • 延长治疗(超过7个月)占64.7%(6363/9828),中位治疗时间242天(IQR 195-348天)。
  • 男性aHR 1.61(95%CI 1.30-2.00,p<0.001)、年龄≥60岁aHR 2.03(95%CI 1.70-2.44,p<0.001)、空洞aHR 1.51(95%CI 1.25-1.82,p<0.001)、2个月痰阳性aHR 1.39(95%CI 1.05-1.81,p=0.02)增加复发风险。
  • 延长治疗与复发风险降低相关(aHR 0.73,95%CI 0.61-0.88,p=0.001)。

临床怎么用

  • 对成功治疗的涂阳肺结核患者,应关注男性、高龄、空洞及2个月痰菌阳性等复发高危因素。
  • 治疗后第一年应加强随访监测,以及时发现复发。

局限性

  • 延长治疗与复发风险降低的关联需进一步分析,不宜直接推断因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Post-treatment recurrence remains a challenge for the global control of tuberculosis (TB). This study investigated longitudinal data on pulmonary TB recurrence rates and risk factors for recurrence among successfully treated smear-positive tuberculosis cases in China. METHODS: Between 1st January 2009 and 31st December 2016 we evaluated 33 441 treatment-naïve patients diagnosed with sputum-smear-positive, non-multidrug-resistant TB in Hangzhou, China. We included the data of 9828 patients with TB who were treated successfully. RESULTS: A total of 4.9% of the cases were recurrent (479/9828), identified within a median observation period lasting 1565 days. Altogether, 51.1% (245/479) of the recurrences occurred within 1 year. The cumulative 2- and 5-year recurrence rates were 3.90% (95% confidence interval (CI) 3.3-4.5%) and 5.4% (95%CI 4.8-6.0%), respectively. Prolonged treatment (over 7 months) occurred in 64.7% (6363/9828), with a median treatment duration of 242 days (interquartile range 195-348 days). Male sex (adjusted hazard ratio (aHR) (95%CI) 1.61 (1.30-2.00), p < 0.001), age 60 years old or older (aHR (95%CI) 2.03 (1.70-2.44), p < 0.001), pulmonary cavity (aHR (95%CI) 1.51 (1.25-1.82), p < 0.001) and sputum positivity at 2 months (aHR (95%CI) 1.39 (1.05-1.81), p 0.02) all increased the risk of TB recurrence. Prolonged treatment was associated with reduced TB recurrence (aHR (95%CI) 0.73 (0.61-0.88), p 0.001). CONCLUSIONS: Recurrence remains a problem for successfully treated patients with sputum-smear-positive pulmonary TB, especially those with independent risk factors. Further analysis of prolonged treatment is required.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Ruan QL, Yang QL, Sun F, et al. Recurrent pulmonary tuberculosis after treatment success: a population-based retrospective study in China. Clin Microbiol Infect. 2021. PMID: 34601149. doi:10.1016/j.cmi.2021.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。